Table 1
Sustained virological response rates in the phase III peginterferon (PEG IFN) pivotal trials
| Interferon | Ribavirin dose | Overall response (%) | Genotype 1 (%) | Genotype non-1 (%) | Genotype 1 + high viral load (%) | Stage 3–4 fibrosis (%) |
|---|---|---|---|---|---|---|
| *Data from the Peg-Intron product insert. | ||||||
| Lindsay4 | ||||||
| PEG IFN α-2b 1.0 μg/kg q wk | Not applicable | 25 | 14 | 47 | 8 | Not available |
| IFN α-2b 3 MIU TIW | Not applicable | 12 | 6 | 28 | 2 | Not available |
| Zeuzem5 | ||||||
| PEG IFN α-2a 180 μg | Not applicable | 39 | 28 | 57 | 14 | 32 |
| IFN α-2a 6/3 MIU TIW | Not applicable | 19 | 7 | 40 | 1 | 7 |
| Heathcote6 (cirrhosis or transition to cirrhosis) | ||||||
| PEG IFN α-2a 180 μg | Not applicable | 30 | 12 | 51 | 10 | 30 |
| IFN α-2a 6/3 MIU TIW | Not applicable | 8 | 2 | 15 | 4 | 8 |
| Manns7 | ||||||
| PEG IFN α-2b 1.5 μg/kg q wk | 800 mg QD | 54 | 42 | 75 | 30* | 44 |
| IFN α-2b 3 MIU TIW | 1000–1200 mg QD | 47 | 33 | 73 | 29* | 41 |
| Fried8 | ||||||
| PEG IFN α-2a 180 μg | 1000–1200 mg QD | 56 | 46 | 76 | 42 | 43 |
| IFN α-2a 3 MIU TIW | 1000–1200 mg QD | 45 | 37 | 61 | 33 | 33 |
